Original Article

You have full text access to this OnlineOpen article

Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas

Data from the SEER program, 1973–2001

  1. Elizabeth B. Claus Ph.D., M.D.1,2,*,
  2. Peter M. Black M.D., Ph.D.2

Article first published online: 8 FEB 2006

DOI: 10.1002/cncr.21733

Issue

Cancer

Cancer

Volume 106, Issue 6, pages 1358–1363, 15 March 2006

Additional Information

How to Cite

Claus, E. B. and Black, P. M. (2006), Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas. Cancer, 106: 1358–1363. doi: 10.1002/cncr.21733

Author Information

  1. 1

    Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut

  2. 2

    Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts

*Department of Epidemiology and Public Health, Yale University School of Medicine, 60 College St., P.O. Box 208034, New Haven, CT 06520–8034

Publication History

  1. Issue published online: 2 MAR 2006
  2. Article first published online: 8 FEB 2006
  3. Manuscript Accepted: 15 SEP 2005
  4. Manuscript Revised: 3 AUG 2005
  5. Manuscript Received: 11 MAY 2005

Funded by

  • National Institutes of Health Grant. Grant Number: 5R25-CA089017–03
  • Brain Science Foundation, Boston, Massachusetts
  • Goldfine family

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (206K)

REFERENCES

  • 1
    Central Brain Tumor Registry ofthe United States (CBTRUS). 2002 tables. Available at URL: http://www.cbtrus.org/2002tables2002_18.htm [accessed January 28, 2004].
  • 2
    SEER Public-Use 1973–2001. Surveillance, Epidemiology, and End Results (SEER) Program Public Use Data (1973–2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
  • 3
    Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histologic subtype: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973–1991. J Neurosurg. 1998; 88: 1–10.
  • 4
    Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy M. The conditional probability of survival of patients with primary malignant brain tumors. Cancer. 1999; 85: 485–491.
    Direct Link:
  • 5
    Olson J, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000; 54: 1442–1448.
  • 6
    Peraud A, Ansari H, Bise K, et al. Clinical outcome of supratentorial astrocytoma WHO grade II. Acta Neurochir. 1998; 140: 1213–1222.
  • 7
    Piepmeier J, Christopher S, Spencer D, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgery. 1996; 38: 872–879.
  • 8
    Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. Neuro-oncol. 1998; 40: 153–160.
  • 9
    Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro-oncol. 1999; 1: 205–211.
  • 10
    Cox DR. Regression models and life tables. J R Stat Soc[B]. 1972; 34: 187–202.
  • 11
    SAS Institute Inc. SAS/STAT user's guide, version 6, 4th ed, volume 1. Cary, NC: SAS Institute Inc., 1989.
  • 12
    Castillo MS, Davis FG, Surawicz T, et al. Consistency of primary brain tumor diagnoses and codes in cancer surveillance systems. Neuroepidemiol. 2004; 23: 85–93.
  • 13
    Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998; 90: 1473–1479.
  • 14
    van den Bent MJ. Advances in the biology and treatment of oligodendrogliomas. Cur Opin Neurol. 2004; 17: 675–680.
  • 15
    Keles GE, Lambern KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of the extent of resection as a factor influencing outcome. J Neurosurg. 2001; 95: 735–745.
  • 16
    Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005; 103: 1227–1233.
    Direct Link:
  • 17
    Black PM, Alexander E III, Martin C, et al. Craniotomy for tumor treatment in an intraoperative magnetic resonance imaging unit. Neurosurgery. 1999; 45: 423–433.
  • 18
    Lipson AC, Gargolio PC, Black PM. Intraoperative magnetic resonance imaging: considerations for the operating room of the future. J Clin Neuroscience. 2001; 8: 305–310.
  • 19
    Nicolato A, Gerosa MA, Fina P, et al. Prognostic factors in low-grade supratentorial astrocytomas: a multivariate statistical analysis in 76 surgically treated adult patients. Surg Neurol. 1995; 44: 208–223.
  • 20
    North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer. 1990; 66: 6–14.
    Direct Link:
  • 21
    Scerrati M, Roselli R, Iacoangeli M, et al. Prognostic factors in low-grade (WHO II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiat. 1996; 61: 291–296.
  • 22
    Shaw EG, Scheithauer BW, O'Fallon JR. Supratentorial glioma: a comparative study by grade and histologic subtype. J Neurooncol. 1997; 31: 273–278.
  • 23
    Trantakis C, Winkler D, Lindner D, et al. Clinical results in MR-guided therapy for malignant gliomas. Acta Neurochir. 2002; 85: 65–71.
  • 24
    Whitton AC, Bloom HJG. Low-grade gliomas of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys. 1990; 18: 783–786.
  • 25
    Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997–1003.
  • 26
    Okcu MF, Selvan M, Wang LE, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clinical Cancer Res. 2004; 10: 2618–2625.
View Full Article (HTML) Get PDF (206K)